Alteration of pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after repeated intravenous administration in dogs
- 1 January 1993
- journal article
- Published by Elsevier in Thrombosis Research
- Vol. 69 (1) , 59-70
- https://doi.org/10.1016/0049-3848(93)90003-7
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Importance of antithrombin therapy during coronary angioplastyJournal of the American College of Cardiology, 1991
- Report on a Discussion Forum: “Medical and Surgical Application of Recombinant Hirudin”Seminars in Thrombosis and Hemostasis, 1991
- Potential use of recombinant hirudin as an anticoagulant in a cardiopulmonary bypass modelThe Annals of Thoracic Surgery, 1991
- The Anticoagulant and Antithrombotic Properties of HirudinsThrombosis and Haemostasis, 1990
- Interaction of site specific hirudin variants with α‐thrombinFEBS Letters, 1988
- Cloning and Expression in Escherichia coli of a Synthetic DNA for Hirudin, the Blood Coagulation Inhibitor in the LeechDNA, 1986
- PharmacokineticsPublished by Taylor & Francis ,1982